The Frequency of HIV-1 Infection in Iranian Children and Determination of the Transmitted Drug Resistance in Treatment-naïve Children.

BACKGROUND The advent of resistance-associated mutations in HIV-1 is a barrier to the success of the ARTs. OBJECTIVE In this study, the abundance of HIV-1 infection in Iranian children, and also detection of the TDR in naïve HIV-1 infected pediatric (under 12 years old) were evaluated. MATERIALS From June 2014 to January 2019, a total of 544 consecutive treatment-naïve HIV-1-infected individuals enrolled in this study. After RNA extraction, amplification, and sequencing of the HIV-1 pol gene, the DRM and phylogenetic analysis were successfully performed on the plasma specimens of the ART-naïve HIV-1-infected-children under 12 years old. The DRMs were recognized using Stanford HIV Drug Resistance Database. RESULTS Out of the 544 evaluated treatment-naïve HIV-1-infected individuals, 15 (2.8%) cases were children under 12 years old. The phylogenetic analyses of the amplified region of pol gene indicated that all of the 15 HIV-1-infected pediatric patients were infected by CRF35_AD, and a total of 13.3% (2/15) of these children were infected with HIV-1 variants with SDRMs (one child harbored two related SDRMs [D67N, V179F], and another child had three related SDRMs [M184V, T215F, and K103N]), according to the last algorithm of the WHO. No PIs-related SDRMs were observed in HIV-1-infected children. CONCLUSION The current study demonstrated that a total of 13.3% of treatment-naïve HIV-1-infected Iranian pediatrics (under 12 years old) were infected with HIV-1 variants with SDRMs. Therefore, it seems that screening to recognize résistance-associated mutations before the initiation of ARTs among Iranian children is essential for favorable medication efficacy and dependable prognosis.

[1]  H. Miot,et al.  Depression and Coping Are Associated with Failure of Adherence to Antiretroviral Therapy Among People Living with HIV/AIDS. , 2019, AIDS research and human retroviruses.

[2]  Stephen A. Rawlings,et al.  Successful optimization of antiretroviral regimens in treatment‐experienced people living with HIV undergoing liver transplantation , 2019, Transplant infectious disease : an official journal of the Transplantation Society.

[3]  Ingrid A. Beck,et al.  Predictors of mortality within the first year of initiating antiretroviral therapy in urban and rural Kenya: A prospective cohort study , 2019, PloS one.

[4]  W. MacLeod,et al.  Adolescent HIV treatment in South Africa's national HIV programme: a retrospective cohort study. , 2019, The lancet. HIV.

[5]  C. Tremblay,et al.  Association between lipodystrophy and length of exposure to ARTs in adult HIV-1 infected patients in Montreal , 2019, BMC Infectious Diseases.

[6]  M. Hughes,et al.  Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. , 2019, The lancet. HIV.

[7]  E. Arts,et al.  The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030 , 2019, Infectious Diseases of Poverty.

[8]  A. Memarnejadian,et al.  HIV-1 Drug Resistance Mutations among Antiretroviral Drug-Experienced Patients in the South of Iran , 2019, Intervirology.

[9]  V. Calvez,et al.  Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali. , 2019, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[10]  M. Lampe,et al.  Epidemiology of Perinatal HIV Transmission in the United States in the Era of Its Elimination. , 2019, The Pediatric infectious disease journal.

[11]  M. Mohraz,et al.  Evaluation of Acquired HIV Drug Resistance among People Living with HIV Who Have Taken Antiretroviral Therapy for 9–15 Months in 14 Triangular Clinics in Iran, 2015–2016 , 2019, Intervirology.

[12]  P. Victor,et al.  Performance of a Modified In-house HIV-1 Avidity Assay among a Cohort of Newly Diagnosed HIV-1 Infected Individuals and the Effect of ART on Maturation of HIV-1 Specific Antibodies. , 2019, Current HIV research.

[13]  H. Xing,et al.  HIV Epidemiology and Prevention in Southwestern China: Trends from 1996-2017 , 2018, Current HIV Research.

[14]  A. Boyko,et al.  Molecular Surveillance of HIV-1 infection in Krasnoyarsk Region, Russia: Epidemiology, Phylodynamics and Phylogeography. , 2019, Current HIV research.

[15]  H. Keyvani,et al.  Investigation of the effects of a prevention of mother-to-child HIV transmission program among Iranian neonates , 2018, Archives of Virology.

[16]  M. Lampe,et al.  Brief Report: Estimated Incidence of Perinatally Acquired HIV Infection in the United States, 1978–2013 , 2017, Journal of acquired immune deficiency syndromes.

[17]  Á. Holguín,et al.  Trends in Drug Resistance Prevalence, HIV-1 Variants and Clinical Status in HIV-1-infected Pediatric Population in Madrid: 1993 to 2015 Analysis , 2017, The Pediatric infectious disease journal.

[18]  R. Shirkoohi,et al.  Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran , 2017, Iranian journal of public health.

[19]  W. Mcfarland,et al.  The First Characterization of HIV-1 Subtypes and Drug Resistance Mutations among Antiretrovirally Treated Patients in Kermanshah, Iran , 2017, Intervirology.

[20]  A. Borkhardt,et al.  HIV-1 Subtype Diversity and Prevalence of Primary Drug Resistance in a Single-Center Pediatric Cohort in Germany , 2017, Intervirology.

[21]  R. Njouom,et al.  HIV Drug Resistance Testing in a Resource Limited Setting with High Viral Diversity: The First Twenty Eight Months Experience. , 2017, Current HIV research.

[22]  R. Shafer,et al.  HIV-1 drug resistance and resistance testing. , 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[23]  S. Khazaei,et al.  Challenges and Proposed Actions for HIV/AIDS Control among Children in Iran , 2016 .

[24]  H. Keyvani,et al.  Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed Patients , 2016, Jundishapur journal of microbiology.

[25]  G. M. Souza,et al.  Transmitted Drug Resistance Among Recently Diagnosed Adults and Children in São Paulo, Brazil. , 2015 .

[26]  S. Rowland-Jones,et al.  Outcomes of prevention of mother to child transmission of the human immunodeficiency virus-1 in rural Kenya—a cohort study , 2015, BMC Public Health.

[27]  M. Mohraz,et al.  Pregnancy through the Lens of Iranian Women with HIV , 2015, Journal of the International Association of Providers of AIDS Care.

[28]  D. Katzenstein,et al.  Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  G. Shanmugam,et al.  Prediction of drug-resistance using genotypic and docking analysis among anti-retroviral therapy naïve and first-line treatment failures in Salem, Tamil Nadu, India. , 2015, Current HIV research.

[30]  S. Kabra,et al.  Mutations in the Reverse Transcriptase and Protease Genes of Human Immunodeficiency Virus-1 from Antiretroviral Naïve and Treated Pediatric Patients , 2015, Viruses.

[31]  R. Kantor,et al.  Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  P. Easterbrook,et al.  Assessment of second-line antiretroviral regimens for HIV therapy in Africa. , 2014, The New England journal of medicine.

[33]  P. Frange,et al.  Missed Opportunities for HIV Testing in Pregnant Women and Children Living in France , 2014, The Pediatric infectious disease journal.

[34]  W. Adebimpe,et al.  Perception on prevention of mother-to-child-transmission (PMTCT) of HIV among women of reproductive age group in Osogbo, Southwestern Nigeria , 2013, International journal of women's health.

[35]  A. Kamarulzaman Fighting the HIV epidemic in the Islamic world , 2013, The Lancet.

[36]  H. Joulaei,et al.  Primary Health Care Strategic Key to Control HIV/AIDS in Iran , 2013, Iranian journal of public health.

[37]  H. Keyvani,et al.  Prevalence of Transmitted HIV Drug Resistance in Iran between 2010 and 2011 , 2013, PloS one.

[38]  F. Ceccherini‐Silberstein,et al.  Emerging patterns and implications of HIV-1 integrase inhibitor resistance , 2012, Current opinion in infectious diseases.

[39]  V. Sreenivas,et al.  Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy. , 2012, Current HIV research.

[40]  Suharni Mohamad,et al.  Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia. , 2012, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[41]  Tommy F. Liu,et al.  Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool , 2012, Journal of Clinical Microbiology.

[42]  R. Mehrdad,et al.  Survey of Human Immunodeficiency Virus-1 Protease Gene Drug Resistance among HIV-infected Patients in an Iranian Research Center for HIV/AIDS , 2012 .

[43]  D. Harris,et al.  HIV Drug Resistance-Associated Mutations in Antiretroviral Naïve HIV-1-Infected Latin American Children , 2011, Advances in virology.

[44]  C. Diazgranados,et al.  Antiretroviral drug resistance in HIV-infected patients in Colombia. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[45]  Zeraati Hojjat,et al.  Preventing Mother-to-Child Transmission of HIV/AIDS: Do Iranian Pregnant Mothers Know about it? , 2010, Journal of reproduction & infertility.

[46]  S. Crowe,et al.  Stability of dried blood spots for HIV-1 drug resistance analysis. , 2010, Current HIV research.

[47]  J. Pinto,et al.  Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically Infected children in Belo Horizonte, Brazil. , 2010, AIDS research and human retroviruses.

[48]  O. Abidi,et al.  The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco. , 2009, Journal of infection in developing countries.

[49]  Anne-Mieke Vandamme,et al.  Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.

[50]  S. Hammer,et al.  Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  S. Sehgal,et al.  High rate of mutation K103N causing resistance to nevirapine in Indian children with acquired immunodeficiency syndrome. , 2008, Indian journal of medical microbiology.

[52]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[53]  D. Bennett,et al.  World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites , 2008, Antiviral therapy.

[54]  M. Hughes,et al.  Neurodevelopmental Functioning in HIV-Infected Infants and Young Children Before and After the Introduction of Protease Inhibitor–Based Highly Active Antiretroviral Therapy , 2007, Pediatrics.

[55]  J. Lindsey,et al.  Growth of Human Immunodeficiency Virus-Infected Children Receiving Highly Active Antiretroviral Therapy , 2005, The Pediatric infectious disease journal.

[56]  J. Temple,et al.  Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. , 2004, Journal of virological methods.

[57]  Thorvaldur Gylfason,et al.  Natural resources, education, and economic development , 2000 .

[58]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[59]  L. Kalish,et al.  Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. , 1997, The New England journal of medicine.

[60]  B. Korber,et al.  Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease , 1997, Journal of virology.

[61]  K. Mcintosh,et al.  Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. , 1996, The Pediatric infectious disease journal.

[62]  B. Larder,et al.  Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. , 1994, The Journal of general virology.

[63]  Qinggang Xu,et al.  Genotypic Methods for HIV Drug Resistance Monitoring: the Opportunities and Challenges Faced by China. , 2019, Current HIV research.

[64]  M. Garcia-deltoro Rapid Initiation of Antiretroviral Therapy after HIV Diagnosis. , 2019, AIDS reviews.

[65]  M. Aghasadeghi,et al.  Comparison of antiretroviral drug resistance among treatment-naive and treated HIV-infected individuals in Shiraz, Iran , 2017, Archives of Virology.

[66]  A. Memarnejadian,et al.  Prevalence of HIV-1 pre-treatment drug resistance in a southern province of Iran, 2016-2017 , 2017, Archives of Virology.

[67]  Huldrych F. Günthard,et al.  Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. , 2012, JAMA.

[68]  A. Meynard,et al.  Developing youth friendly primary care services in Bosnia & Herzegovina. , 2009 .

[69]  A. Tafti,et al.  Knowledge and attitude about HIV/AIDS among pregnant women in Yazd, Iran , 2006 .